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2466of “traditional” linear lines and electrogram-based
ablation after pulmonary vein (PV) isolation are
disappointingly low and indicate the need for new
substrate-targeted ablation strategies for atrial ﬁbril-
lation (AF) therapy.
Drs. Sramko and Kautzner commented on the
complex pathophysiology of AF. In fact, there is
general agreement about the complexity of the roles
of triggers (especially but not exclusively from the
PVs), of the substrate (including atrial ﬁbrosis), and of
a variety of modulators/modiﬁers (including hyper-
tension, obesity, and other cardiac risk factors, but
also inﬂammation, cancer, and other conditions). We
have analyzed data from intraoperatively obtained
specimen, post-mortem autopsy ﬁndings, electro-
anatomic voltage mapping (EAVM) studies, and
delayed enhancement (DE) magnetic resonance im-
aging (MRI) investigations, all of them supporting the
role of atrial ﬁbrosis for the human AF substrate, but
questioning “traditional wisdom” such as AF begets
AF and also the etiological role of age (2,3). Recently,
atrial ﬁbrosis was described to appear to be “a com-
mon endpoint of a wide range of AF-promoting con-
ditions” (4).
Drs. Sramko and Kautzner commented in addi-
tion on the role of DE MRI as well as EAVM as
imaging/mapping techniques or surrogates for atrial
ﬁbrosis. With respect to DE MRI, we have indicated
in our manuscript that “this modality requires
extensive MRI experience, and its reproducibility is
still under investigation in other groups” (1). In
general, new strategies and technologies that are
introduced into clinical practice always have limi-
tations. In order to appreciate the current limita-
tions of our proposed new techniques, we included
a “limitations” paragraph, which is indeed the
longest in our whole manuscript (1). However,
despite all limitations inherent to new techniques/
technologies, we see the future role for our pro-
posed strategies including the “box isolation of
ﬁbrotic areas,” and several clinical studies are
currently being performed already.
Overall, although it seems that we look from dif-
ferent angles, we indeed appreciate all comments
from Drs. Sramko and Kautzner because an open and
respectful discussion helps to further develop the
promising ﬁeld of substrate modiﬁcation in AF abla-
tion for our patients.*Hans Kottkamp, MD
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Complex Interplay of Anatomic,
Physiologic, and Outcome DataThe review by Arbab-Zadeh and Fuster advocates
for the assessment of atherosclerotic disease burden
as opposed to individual plaque vulnerability in
patients at risk for cardiac events. It also cites a
post hoc analysis of the COURAGE (Clinical Out-
comes Utilizing Revascularization and Aggressive
Drug Evaluation) trial, stating that angiographic
data (clearly not the optimal way to assess athero-
sclerotic burden) are superior to myocardial
ischemia testing in predicting outcome. So is the
predictive value of ischemia assessment simply a
reﬂection of atherosclerotic burden? The results of
combined studies for disease burden, ischemia, and
outcomes in different patient populations tend
mostly to disagree.
A study by Schenker et al. (1) evaluated 695
consecutive intermediate-risk patients undergoing
combined positron emission tomography perfusion
imaging and coronary calcium scoring. Patients with
ischemia carried a higher event rate at all levels of
coronary calcium. In another study of 541 patients
with suspected coronary disease undergoing coronary
computed tomography (CT) angiography and single-
photon emission computed tomography (SPECT)
myocardial perfusion imaging (MPI), anatomic and
functional information was synergistic (2). MPI in-
formation remained signiﬁcant in multivariate
models and the event rates between patients with
none or mild coronary stenosis and abnormal MPI and
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2467patients with signiﬁcant coronary stenosis did not
differ signiﬁcantly. In a study of 1,295 patients with
suspected coronary disease who underwent both
coronary CT angiography and SPECT within 90 days
sequential use of these modalities showed an incre-
mental prognostic value (3). Another study of 462
patients showed that patients with “matched” coro-
nary calcium abnormality and perfusion defects on
SPECT MPI have worse prognosis compared to pa-
tients with “unmatched” ﬁndings. A study of 1,126
asymptomatic subjects undergoing SPECT MPI and
coronary calcium scoring showed independent and
complementary predictions of cardiac events by both
modalities (4). In a study of patients with known cor-
onary disease, both high calcium score and abnormal
MPI carried independent prognostic information.
In a study of patients undergoing pre-operative
SPECT MPI and calcium scoring before noncardiac
surgery both variables carried incremental prognostic
information (5).
The anatomic data on atherosclerotic disease
burden (such as coronary calcium scoring or plaque
burden on coronary CT angiography) are clearly a
major determinant of adverse cardiovascular events.
This is especially relevant in the current era with
progressively declining rates of ischemia on func-
tional studies. At the same time, most of the com-
bined studies for disease burden, ischemia, and
outcomes suggest that functional data are not a sim-
ple reﬂection of atherosclerotic burden but may carry
independent prognostic information.*Edgar Argulian, MD, MPH
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We agree with Dr. Argulian that the relationship be-
tween characteristics of coronary heart disease and
adverse cardiac events is complex and the contribu-
tion of individual factors difﬁcult to isolate. We
maintain, however, that the bulk of evidence favors
the atherosclerotic disease burden as the predomi-
nant factor for predicting myocardial infarction and
cardiac death (1). Dr. Argulian referenced several ar-
ticles to support his position of incremental value of
ischemia testing for risk prediction, but we would like
to offer alternative interpretations of these studies.
The paper by Schenker et al. (2) in fact shows no
statistically signiﬁcant differences among event rates
in patients with the same coronary artery calcium
score (CACS) categories who have or do not have
provocable myocardial ischemia. The study by Chang
et al. (3) reveals adverse event risks in patients with
normal myocardial perfusion studies ranging from
low to high depending on the CACS, demonstrating
the dependence of risk on disease burden. Dr. Argu-
lian lists other studies suggesting synergistic infor-
mation of CACS and ischemia testing for event
prediction but it remains unclear if these effects are
merely the result of categorizing test results because
area under the curve analysis using continuous vari-
ables was performed in none of these reports. In
fact, a recent analysis that did use area under the
curve data showed better performance of CACS than
ischemia testing and similar to combining both (4).
Coronary calcium scanning accounts for neither non-
calciﬁed atherosclerotic disease nor disease location—
both may provide additional prognostic information.
While data are consistent in demonstrating a strong
relationship between atherosclerotic disease burden
and risk of adverse events, other factors may serve
as modiﬁers. It remains to be seen which modiﬁers
are most meaningful in this context.*Armin Arbab-Zadeh, MD, PhD
Valentin Fuster, MD, PhD
*Johns Hopkins University
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